NDRG1 prognosticates the natural course of disease in WHO grade II glioma

Journal of Neuro-Oncology

Volumn 117, Issue 1, 2014, Pages 25-32

  Blaes, J ^a,b   Weiler, M ^a,b   Sahm, F ^a,b   Hentschel, B ^c   Osswald, M ^a,b   Czabanka, M ^d   Thome C M ^a   Schliesser, M G ^a   Pusch, S ^a,b   Luger, S ^a   Winkler, F ^a,b   Radbruch, A ^b   Jugold, M ^a   Simon, M ^e   Steinbach, J P ^f   Schackert, G ^g   Tatagiba, M ^h   Westphal, M ⁱ   Tonn, J C ^j   Gramatzki, D ^k   Pietsch, T ^e   Hartmann, C ^a,b   Glimm, H ^a   Vajkoczy, P ^d   Von Deimling, A ^a,b   Platten, M ^a,b   Weller, M ^k   Wick, W ^a,b   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h UNIVERSITY OF TÜBINGEN   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j UNIVERSITY OF MUNICH   (Germany)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

Biomarker; Brain tumor; Glioma; NDRG1; Prognosis

Indexed keywords

ALKYLATING AGENT; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; GENE EXPRESSION; GENE TARGETING; GENOTOXICITY; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE; ONCOGENE NDRG1; POSTOPERATIVE CARE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ASTROCYTOMA; BRAIN NEOPLASMS; CELL CYCLE PROTEINS; FOLLOW-UP STUDIES; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; NEOPLASM GRADING; OLIGODENDROGLIOMA; PROGNOSIS; PROSPECTIVE STUDIES; RETREATMENT; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901619304     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1357-2     Document Type: Article

References (33)

1. Parsons DW, Jones S, Zhang X, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812
2. Wick W, Hartmann C, Engel C, et al. (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. J Clin Oncol 27:5874-5880
3. Sanson M, Marie Y, Paris S, et al. (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154
4. Hartmann C, Hentschel B, Wick W, et al. (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707-718
5. Weller M, Felsberg J, Hartmann C, et al. (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27:5743-5750
6. Van den Bent MJ, Dubbink HJ, Marie Y, et al. (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597-1604
7. Dubbink HJ, Taal W, van Marion R, et al. (2009) IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73:1792-1795
8. Hartmann C, Hentschel B, Tatagiba M, et al. (2011) Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 17:4588-4599
9. Hegi ME, Diserens AC, Gorlia T, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
10. Wick W, Platten M, Meisner C, et al. (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707-715
11. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J Clin Oncol 31:344-350
12. Cairncross G, Wang M, Shaw E, et al. (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337-343
13. Wick W, Meisner C, Hentschel B, et al. (2013) Prognostic or predictive value of MGMT promoter methylation in malignant gliomas depends on IDH1 mutation. Neurology 81:1515-1522
14. Weller M, Berger H, Hartmann C, et al. (2007) Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13:6933-6937
15. van den Bent MJ, Afra D, de Witte O, et al. (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985-990
16. Shaw EG, Wang M, Coons SW, et al. (2012) Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 30:3065-3070
17. Sun B, Chu D, Li W, Chu X, Li Y, Wei D, Li H (2009) Decreased expression of NDRG1 in glioma is related to tumor progression and survival of patients. J Neurooncol 94:213-219
18. Northcott PA, Shih DJ, Peacock J, et al. (2012) Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488:49-56
19. Weiler M, Blaes J, Sahm F, et al. (2013) mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci USA. doi: 10.1073/pnas.1314469111
20. Louis DN, Ohgaki H, Wiestler OD, et al. (2007) The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 114:97-109
21. Pignatti F, van den Bent M, Curran D, et al. (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076-2084
22. Bruna A, Darken RS, Rojo F, et al. (2007) High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11:147-160
23. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120:567-584
24. Tabatabai G, Stupp R, van den Bent MJ, et al. (2010) Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol 120:585-592
25. Koelsche C, Sahm F, Capper D, et al. (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 126:907-915
26. Wiestler B, Capper D, Holland-Letz T, et al. (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443-451
27. Kurdistani SK, Arizti P, Reimer CL, Sugrue MM, Aaronson SA, Lee SW (1998) Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res 58:4439-4444
28. Maruyama Y, Ono M, Kawahara A, et al. (2006) Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res 66:6233-6242
29. Yan X, Chua MS, Sun H, So S (2008) N-Myc down-regulated gene 1 mediates proliferation, invasion, and apoptosis of hepatocellular carcinoma cells. Cancer Lett 262:133-142
30. Bandyopadhyay S, Pai SK, Hirota S, et al. (2004) Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene 23:5675-5681
31. Koshiji M, Kumamoto K, Morimura K, et al. (2007) Correlation of N-myc downstream-regulated gene 1 expression with clinical outcomes of colorectal cancer patients of different race/ethnicity. World J Gastroenterol 13:2803-2810
32. Chua MS, Sun H, Cheung ST, et al. (2007) Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod Pathol 20:76-83
33. Nishio S, Ushijima K, Tsuda N, et al. (2008) Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma. Cancer Lett 264:36-43